{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T09:47:21Z","timestamp":1774864041838,"version":"3.50.1"},"reference-count":37,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Pulmonary hypertension (PH) remains a progressive and life-threatening condition despite advances in targeted pharmacotherapy. Pulmonary artery denervation (PADN) has emerged as a novel interventional strategy aimed at modulating sympathetic overactivity and improving pulmonary vascular hemodynamics. Methods: A comprehensive search of PubMed, EMBASE, Scopus, Web of Science, and the Cochrane Library was conducted through December 2024. Randomized clinical trials and prospective observational studies assessing PADN in PH were included. Primary endpoints were changes in outcomes from six-minute walk distance (6MWD), mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), cardiac output (CO), and right ventricular function parameters. Secondary outcomes included clinical worsening, rehospitalization, transplantation, and all-cause mortality. Random-effects models were used to calculate pooled mean differences (MDs) and odds ratios (ORs) with 95% confidence intervals (CIs). Subgroup analyses were performed according to pulmonary hypertension phenotype and study design, and sensitivity analyses were conducted to assess robustness of pooled estimates. Results: Nine studies involving 454 patients were included. PADN significantly improved functional capacity (6MWD: MD = 92.03 m; 95% CI 46.37\u2013137.68; p &lt; 0.001) and reduced mPAP (MD = \u221211.84 mmHg; p &lt; 0.001) and PVR (MD = \u22124.88; p &lt; 0.001). Cardiac output increased significantly (MD = 0.55 L\/min; p &lt; 0.001), with improvements observed in right ventricular functional indices. PADN was associated with a lower risk of clinical worsening (OR = 0.30; p = 0.001) and rehospitalization (OR = 0.07; p &lt; 0.001), whereas no significant difference was observed in all-cause mortality (OR = 0.53; p = 0.12). Considerable heterogeneity was observed across functional and hemodynamic outcomes, reflecting variability in study design, patient populations, and PADN techniques. Conclusions: PADN significantly improves exercise capacity and pulmonary hemodynamics in patients with PH, particularly in those with persistent symptoms despite medical therapy. Although PADN reduces clinical deterioration and rehospitalization, its impact on long-term survival remains uncertain. Further large-scale, multicenter randomized trials are needed to better define optimal patient selection and determine long-term clinical benefit.<\/jats:p>","DOI":"10.3390\/jcm15072619","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:22:36Z","timestamp":1774858956000},"page":"2619","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and Hemodynamic Effects of Pulmonary Artery Denervation in Pulmonary Hypertension Despite Optimized Pharmacotherapy: An Updated Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3675-423X","authenticated-orcid":false,"given":"Elif Ijlal","family":"Cekirdekci","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Kyrenia, Kyrenia 99320, Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-9029","authenticated-orcid":false,"given":"Lutfi Cagatay","family":"Onar","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Republic of Turkey Ministry of Health, Dr. Ismail Fehmi Cumalioglu City Hospital, Tekirdag 59020, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2401324","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jacc.2009.04.006","article-title":"Inflammation, growth factors, and pulmonary vascular remodeling","volume":"54","author":"Hassoun","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1801916","DOI":"10.1183\/13993003.01916-2018","article-title":"Paediatric pulmonary arterial hypertension: Updates on definition, classification, diagnostics and management","volume":"53","author":"Rosenzweig","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.5603\/CJ.a2020.0186","article-title":"The progress of pulmonary artery denervation","volume":"29","author":"Xie","year":"2022","journal-title":"Cardiol. J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Davies, M.G., Miserlis, D., and Hart, J.P. (2022). Current status of pulmonary artery denervation. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.972256"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.tcm.2020.04.005","article-title":"Pulmonary artery denervation for pulmonary arterial hypertension","volume":"31","author":"Constantine","year":"2021","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e002569","DOI":"10.1161\/CIRCINTERVENTIONS.115.002569","article-title":"Pulmonary artery denervation reduces pulmonary artery pressure and induces histological changes in an acute porcine model of pulmonary hypertension","volume":"8","author":"Rothman","year":"2015","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ehf2.14616","article-title":"Autonomic nervous modulation: Early treatment in pulmonary artery hypertension","volume":"11","author":"Liu","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.jacc.2013.06.032","article-title":"New treatment strategies in pulmonary arterial hypertension: Hopes or hypes?","volume":"62","author":"Manes","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1016\/j.jcin.2015.09.015","article-title":"Pulmonary artery denervation attenuates pulmonary arterial remodeling in dogs with pulmonary arterial hypertension","volume":"8","author":"Zhou","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Liu, C., Jiang, X.-M., Zhang, J., Li, B., Li, J., Xie, D.-J., and Hu, Z.-Y. (2016). Pulmonary artery denervation improves right ventricular dysfunction by modulating local RAAS in pulmonary arterial hypertension. BMC Cardiovasc. Disord., 16.","DOI":"10.1186\/s12872-016-0366-4"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2013.05.075","article-title":"Pulmonary artery denervation to treat pulmonary arterial hypertension: The first-in-man PADN-1 study","volume":"62","author":"Chen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e002837","DOI":"10.1161\/CIRCINTERVENTIONS.115.002837","article-title":"Hemodynamic, functional, and clinical responses to pulmonary artery denervation in patients with pulmonary arterial hypertension: Phase II results from the PADN-1 study","volume":"8","author":"Chen","year":"2015","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/24748706.2017.1315204","article-title":"Assessment and prognostic impact of right ventricular function in patients with pulmonary arterial hypertension undergoing pulmonary artery denervation","volume":"1","author":"Chen","year":"2017","journal-title":"Struct. Heart"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.jcin.2022.09.013","article-title":"Pulmonary artery denervation for pulmonary arterial hypertension: A sham-controlled randomized PADN-CFDA trial","volume":"15","author":"Zhang","year":"2022","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jcin.2018.09.021","article-title":"Pulmonary artery denervation significantly increases 6-min walk distance in combined pre- and post-capillary pulmonary hypertension: PADN-5 study","volume":"12","author":"Zhang","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.jchf.2023.05.016","article-title":"Three-year outcomes in patients with combined precapillary and postcapillary pulmonary hypertension: Results from the PADN-5 trial","volume":"11","author":"Zhang","year":"2023","journal-title":"JACC Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jcin.2019.12.027","article-title":"Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension (TROPHY1): Multicenter early feasibility study","volume":"13","author":"Rothman","year":"2020","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.4244\/EIJ-D-23-00349","article-title":"A sham-controlled randomised trial of pulmonary artery denervation for group 1 pulmonary arterial hypertension: One-year outcomes of the PADN-CFDA trial","volume":"19","author":"Kan","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.18087\/cardio.2018.4.10105","article-title":"Radiofrequency pulmonary artery ablation for treatment of residual pulmonary hypertension after pulmonary endarterectomy","volume":"58","author":"Chernyavskiy","year":"2018","journal-title":"Kardiologiia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jacc.2020.06.064","article-title":"Pulmonary artery denervation for patients with residual pulmonary hypertension after pulmonary endarterectomy","volume":"76","author":"Romanov","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.26502\/fccm.92920024","article-title":"Simplicity Denervation System for Pulmonary Artery Denervation in Patients with Residual Pulmonary Hypertension after Pulmonary Thromboembolism and Surgical Thrombectomy","volume":"1","author":"Rudenko","year":"2017","journal-title":"Cardiol. Cardiovasc. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101776","DOI":"10.1016\/j.cpcardiol.2023.101776","article-title":"Pulmonary artery denervation as a new therapeutic option for pulmonary hypertension: A systematic review and meta-analysis","volume":"48","author":"Salazar","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: A proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., and Brennan, S.E. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372.","DOI":"10.1136\/bmj.n71"},{"key":"ref_27","unstructured":"PROSPERO (2025, August 21). International Prospective Register of Systematic Reviews. Available online: https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251038443."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014A web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp. Clin. Trials"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Borenstein, M., Hedges, L., Higgins, J., and Rothstein, H. (Comprehensive Meta-Analysis, 2022). Comprehensive Meta-Analysis, Version 4.","DOI":"10.1002\/9781119099369.ch27"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Wan, X., Wang, W., Liu, J., and Tong, T. (2014). Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-135"},{"key":"ref_33","unstructured":"(Review Manager (Cochrane\u2019s RevMan), 2024). Review Manager (Cochrane\u2019s RevMan), Version 5.4."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1002\/ehf2.14842","article-title":"Pulmonary artery denervation versus conventional therapies for PAH: A systematic review and updated network meta-analysis","volume":"11","author":"Wu","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"133078","DOI":"10.1016\/j.ijcard.2025.133078","article-title":"Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis","volume":"427","author":"Abouzid","year":"2025","journal-title":"Int. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1801897","DOI":"10.1183\/13993003.01897-2018","article-title":"Pulmonary hypertension due to left heart disease","volume":"53","author":"Tedford","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1253\/circrep.CR-24-0179","article-title":"Pulmonary artery denervation for medication refractory pulmonary hypertension (PARPH study): Study protocol for a prospective, open-label, single-arm clinical trial","volume":"7","author":"Asano","year":"2025","journal-title":"Circ. Rep."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2619\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:47:27Z","timestamp":1774860447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/7\/2619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":37,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jcm15072619"],"URL":"https:\/\/doi.org\/10.3390\/jcm15072619","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]}}}